Pregabalin add-on for drug-resistant partial epilepsy

Keyphrases

• Multidrug-resistant 100%
• Partial Epilepsy 100%
• Pregabalin 100%
• Confidence Interval 45%
• Relative Risk 45%
• Placebo 27%
• Adverse Events 18%
• Epilepsy 18%
• Treatment Withdrawal 18%
• Seizure Reduction 18%
• Treatment-resistant 18%
• United Kingdom 9%
• Pfizer 9%
• Cochrane 9%
• Randomized Controlled Trial 9%
• Plateaued 9%
• Improved Outcomes 9%
• MEDLINE 9%
• Cochrane Library 9%
• Adverse Effects 9%
• Intention-to-treat 9%
• Prevalence Estimation 9%
• Seizure 9%
• Drug Treatment 9%
• Antiepileptic Drugs 9%
• Seizure Frequency 9%
• Weight Gain 9%
• Tolerability 9%
• Extracted Data 9%
• Ataxia 9%
• Dizziness 9%
• Increased Dose 9%
• Drug Refractory 9%
• Trial Data 9%
• Cochrane Central Register of Controlled Trials 9%
• Clinical Decision-making 9%
• Response Time Analysis 9%
• Ongoing Trials 9%
• Issue 2 9%
• Double-blind Trial 9%
• Somnolence 9%
• Review Authors 9%
• Chronic Neurological Diseases 9%
• Refractory Partial Epilepsy 9%
• Seizure Freedom 9%
• New Antiepileptic Drugs 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Focal Epilepsy 100%
• Pregabalin 100%
• Placebo 27%
• Adverse Event 18%
• Anticonvulsive Agent 18%
• Prevalence 9%
• Randomized Controlled Trial 9%
• Neurologic Disease 9%
• Pharmacotherapy 9%
• Tolerability 9%
• Ataxia 9%
• Somnolence 9%
• Dizziness 9%